Phathom submits NDA to US FDA for vonoprazan to treat erosive esophagitis

By vbandhakavi

Phathom Pharmaceuticals has announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for its oral therapy vonoprazan to treat erosive esophagitis (EE), a major gastroesophageal reflux disease (GERD) type.